Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

Andrew M. Intlekofer, Erel Joffe, Connie L. Batlevi, Patrick Hilden, Jie He, Venkatraman E. Seshan, Andrew D. Zelenetz, M. Lia Palomba, Craig Moskowitz, Carol Portlock, David J. Straus, Ariela Noy, Steven M. Horwitz, John F. Gerecitano, Alison Moskowitz, Paul Hamlin, Matthew J. Matasar, Anita Kumar, Marcel R. Van Den Brink, Kristina M. KnappJanine D. Pichardo, Michelle K. Nahas, Sally E. Trabucco, Tariq Mughal, Amanda R. Copeland, Elli Papaemmanuil, Mathai Moarii, Ross L. Levine, Ahmet Dogan, Vincent A. Miller, Anas Younes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used targeted sequencing of genes altered in hematologic malignancies, including DNA coding sequence for 405 genes, noncoding sequence for 31 genes, and RNA coding sequence for 265 genes (FoundationOne-Heme). Short variants, rearrangements, and copy number alterations were determined. We studied 198 samples (114 de novo, 58 previously treated, and 26 large-cell transformation from follicular lymphoma). Median number of GAs per case was 6, with 97% of patients harboring at least one alteration. Recurrent GAs were detected in genes with established roles in DLBCL pathogenesis (e.g. MYD88, CREBBP, CD79B, EZH2), as well as notable differences compared to prior studies such as inactivating mutations in TET2 (5%). Less common GAs identified potential targets for approved or investigational therapies, including BRAF, CD274 (PD-L1), IDH2, and JAK1/2. TP53 mutations were more frequently observed in relapsed/refractory DLBCL, and predicted for lack of response to first-line chemotherapy, identifying a subset of patients that could be prioritized for novel therapies. Overall, 90% (n = 169) of the patients harbored a GA which could be explored for therapeutic intervention, with 54% (n = 107) harboring more than one putative target.

Original languageEnglish (US)
Article number60
JournalBlood Cancer Journal
Volume8
Issue number6
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
RNA
DNA
Genes
Mutation
Investigational Therapies
Follicular Lymphoma
Hematologic Neoplasms
Heme
Paraffin
Formaldehyde
Biopsy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Intlekofer, A. M., Joffe, E., Batlevi, C. L., Hilden, P., He, J., Seshan, V. E., ... Younes, A. (2018). Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 8(6), [60]. https://doi.org/10.1038/s41408-018-0089-0

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. / Intlekofer, Andrew M.; Joffe, Erel; Batlevi, Connie L.; Hilden, Patrick; He, Jie; Seshan, Venkatraman E.; Zelenetz, Andrew D.; Palomba, M. Lia; Moskowitz, Craig; Portlock, Carol; Straus, David J.; Noy, Ariela; Horwitz, Steven M.; Gerecitano, John F.; Moskowitz, Alison; Hamlin, Paul; Matasar, Matthew J.; Kumar, Anita; Van Den Brink, Marcel R.; Knapp, Kristina M.; Pichardo, Janine D.; Nahas, Michelle K.; Trabucco, Sally E.; Mughal, Tariq; Copeland, Amanda R.; Papaemmanuil, Elli; Moarii, Mathai; Levine, Ross L.; Dogan, Ahmet; Miller, Vincent A.; Younes, Anas.

In: Blood Cancer Journal, Vol. 8, No. 6, 60, 01.06.2018.

Research output: Contribution to journalArticle

Intlekofer, AM, Joffe, E, Batlevi, CL, Hilden, P, He, J, Seshan, VE, Zelenetz, AD, Palomba, ML, Moskowitz, C, Portlock, C, Straus, DJ, Noy, A, Horwitz, SM, Gerecitano, JF, Moskowitz, A, Hamlin, P, Matasar, MJ, Kumar, A, Van Den Brink, MR, Knapp, KM, Pichardo, JD, Nahas, MK, Trabucco, SE, Mughal, T, Copeland, AR, Papaemmanuil, E, Moarii, M, Levine, RL, Dogan, A, Miller, VA & Younes, A 2018, 'Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay', Blood Cancer Journal, vol. 8, no. 6, 60. https://doi.org/10.1038/s41408-018-0089-0
Intlekofer, Andrew M. ; Joffe, Erel ; Batlevi, Connie L. ; Hilden, Patrick ; He, Jie ; Seshan, Venkatraman E. ; Zelenetz, Andrew D. ; Palomba, M. Lia ; Moskowitz, Craig ; Portlock, Carol ; Straus, David J. ; Noy, Ariela ; Horwitz, Steven M. ; Gerecitano, John F. ; Moskowitz, Alison ; Hamlin, Paul ; Matasar, Matthew J. ; Kumar, Anita ; Van Den Brink, Marcel R. ; Knapp, Kristina M. ; Pichardo, Janine D. ; Nahas, Michelle K. ; Trabucco, Sally E. ; Mughal, Tariq ; Copeland, Amanda R. ; Papaemmanuil, Elli ; Moarii, Mathai ; Levine, Ross L. ; Dogan, Ahmet ; Miller, Vincent A. ; Younes, Anas. / Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. In: Blood Cancer Journal. 2018 ; Vol. 8, No. 6.
@article{111f08df5dc844d8a6056366687a331c,
title = "Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay",
abstract = "We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used targeted sequencing of genes altered in hematologic malignancies, including DNA coding sequence for 405 genes, noncoding sequence for 31 genes, and RNA coding sequence for 265 genes (FoundationOne-Heme). Short variants, rearrangements, and copy number alterations were determined. We studied 198 samples (114 de novo, 58 previously treated, and 26 large-cell transformation from follicular lymphoma). Median number of GAs per case was 6, with 97{\%} of patients harboring at least one alteration. Recurrent GAs were detected in genes with established roles in DLBCL pathogenesis (e.g. MYD88, CREBBP, CD79B, EZH2), as well as notable differences compared to prior studies such as inactivating mutations in TET2 (5{\%}). Less common GAs identified potential targets for approved or investigational therapies, including BRAF, CD274 (PD-L1), IDH2, and JAK1/2. TP53 mutations were more frequently observed in relapsed/refractory DLBCL, and predicted for lack of response to first-line chemotherapy, identifying a subset of patients that could be prioritized for novel therapies. Overall, 90{\%} (n = 169) of the patients harbored a GA which could be explored for therapeutic intervention, with 54{\%} (n = 107) harboring more than one putative target.",
author = "Intlekofer, {Andrew M.} and Erel Joffe and Batlevi, {Connie L.} and Patrick Hilden and Jie He and Seshan, {Venkatraman E.} and Zelenetz, {Andrew D.} and Palomba, {M. Lia} and Craig Moskowitz and Carol Portlock and Straus, {David J.} and Ariela Noy and Horwitz, {Steven M.} and Gerecitano, {John F.} and Alison Moskowitz and Paul Hamlin and Matasar, {Matthew J.} and Anita Kumar and {Van Den Brink}, {Marcel R.} and Knapp, {Kristina M.} and Pichardo, {Janine D.} and Nahas, {Michelle K.} and Trabucco, {Sally E.} and Tariq Mughal and Copeland, {Amanda R.} and Elli Papaemmanuil and Mathai Moarii and Levine, {Ross L.} and Ahmet Dogan and Miller, {Vincent A.} and Anas Younes",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41408-018-0089-0",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

AU - Intlekofer, Andrew M.

AU - Joffe, Erel

AU - Batlevi, Connie L.

AU - Hilden, Patrick

AU - He, Jie

AU - Seshan, Venkatraman E.

AU - Zelenetz, Andrew D.

AU - Palomba, M. Lia

AU - Moskowitz, Craig

AU - Portlock, Carol

AU - Straus, David J.

AU - Noy, Ariela

AU - Horwitz, Steven M.

AU - Gerecitano, John F.

AU - Moskowitz, Alison

AU - Hamlin, Paul

AU - Matasar, Matthew J.

AU - Kumar, Anita

AU - Van Den Brink, Marcel R.

AU - Knapp, Kristina M.

AU - Pichardo, Janine D.

AU - Nahas, Michelle K.

AU - Trabucco, Sally E.

AU - Mughal, Tariq

AU - Copeland, Amanda R.

AU - Papaemmanuil, Elli

AU - Moarii, Mathai

AU - Levine, Ross L.

AU - Dogan, Ahmet

AU - Miller, Vincent A.

AU - Younes, Anas

PY - 2018/6/1

Y1 - 2018/6/1

N2 - We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used targeted sequencing of genes altered in hematologic malignancies, including DNA coding sequence for 405 genes, noncoding sequence for 31 genes, and RNA coding sequence for 265 genes (FoundationOne-Heme). Short variants, rearrangements, and copy number alterations were determined. We studied 198 samples (114 de novo, 58 previously treated, and 26 large-cell transformation from follicular lymphoma). Median number of GAs per case was 6, with 97% of patients harboring at least one alteration. Recurrent GAs were detected in genes with established roles in DLBCL pathogenesis (e.g. MYD88, CREBBP, CD79B, EZH2), as well as notable differences compared to prior studies such as inactivating mutations in TET2 (5%). Less common GAs identified potential targets for approved or investigational therapies, including BRAF, CD274 (PD-L1), IDH2, and JAK1/2. TP53 mutations were more frequently observed in relapsed/refractory DLBCL, and predicted for lack of response to first-line chemotherapy, identifying a subset of patients that could be prioritized for novel therapies. Overall, 90% (n = 169) of the patients harbored a GA which could be explored for therapeutic intervention, with 54% (n = 107) harboring more than one putative target.

AB - We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used targeted sequencing of genes altered in hematologic malignancies, including DNA coding sequence for 405 genes, noncoding sequence for 31 genes, and RNA coding sequence for 265 genes (FoundationOne-Heme). Short variants, rearrangements, and copy number alterations were determined. We studied 198 samples (114 de novo, 58 previously treated, and 26 large-cell transformation from follicular lymphoma). Median number of GAs per case was 6, with 97% of patients harboring at least one alteration. Recurrent GAs were detected in genes with established roles in DLBCL pathogenesis (e.g. MYD88, CREBBP, CD79B, EZH2), as well as notable differences compared to prior studies such as inactivating mutations in TET2 (5%). Less common GAs identified potential targets for approved or investigational therapies, including BRAF, CD274 (PD-L1), IDH2, and JAK1/2. TP53 mutations were more frequently observed in relapsed/refractory DLBCL, and predicted for lack of response to first-line chemotherapy, identifying a subset of patients that could be prioritized for novel therapies. Overall, 90% (n = 169) of the patients harbored a GA which could be explored for therapeutic intervention, with 54% (n = 107) harboring more than one putative target.

UR - http://www.scopus.com/inward/record.url?scp=85048357368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048357368&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0089-0

DO - 10.1038/s41408-018-0089-0

M3 - Article

C2 - 29895903

AN - SCOPUS:85048357368

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 6

M1 - 60

ER -